Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Revealing the mechanisms of ribosome biogenesis dysregulation that drive tumor growth and stress resistance in pancreatic ductal adenocarcinoma

EF 2025-26

Résumé
Pancreatic cancer is the second deadliest cancer in Canada. Of these, most cases are pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form that has oncogenic mutations in a key gene called KRAS. However, direct targeting of KRAS by pharmacological means has proven notoriously difficult. Therefore, understanding the cellular processes that sustain tumor growth and survival in KRAS-mutant cancer cells is critical for developing new treatments for PDAC. Crucially, A key feature of KRAS-driven PDAC is disruption in the cellular production of ribosomes, the protein factories of the cell, which allow cancer cells to ramp up protein production to support tumor growth. Pharmacological inhibition of ribosome production inhibits PDAC tumor growth in animal models, pinpointing this as a potential therapeutic strategy. However, little is known about the precise mechanism of how KRAS alters ribosome production. In our preliminary study, we identified a protein named Dhx15 to be important for ribosome production only in mutant KRAS-harbouring PDAC cells, revealing the exciting possibility that ribosome production may be safely targeted without affecting normal tissues. To assess this, I will combine classic biochemical methods and new sequencing approaches to comprehensively characterize the impact of Dhx15 on the molecular mechanism of ribosome production in cells with or without KRAS mutation. As PDAC cells also frequently encounter hypoxic stress (lack of oxygen due to poor blood supply to the tumor), I will also investigate if molecular changes in ribosome production help tumor cells survive hypoxia. Using state-of-the-art biochemical, genomic, and proteomic approaches, I will map the KRAS-driven changes in ribosome production that support PDAC, revealing new vulnerabilities of PDAC tumor cells that may be therapeutically exploited.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
537036
Name
Yan Junran
Country
United Kingdom
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Revealing the mechanisms of ribosome biogenesis dysregulation that drive tumor growth and stress resistance in pancreatic ductal adenocarcinoma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Cancer Therapy; Hypoxia; Kras; Mechanism Driving Cancer Development; Nanopore; Nucleolus; Pancreatic Cancer; Proteomics; Ribosome Biogenesis; Rna Processing
Abstract
Pancreatic cancer is the second deadliest cancer in Canada. Of these, most cases are pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form that has oncogenic mutations in a key gene called KRAS. However, direct targeting of KRAS by pharmacological means has proven notoriously difficult. Therefore, understanding the cellular processes that sustain tumor growth and survival in KRAS-mutant cancer cells is critical for developing new treatments for PDAC. Crucially, A key feature of KRAS-driven PDAC is disruption in the cellular production of ribosomes, the protein factories of the cell, which allow cancer cells to ramp up protein production to support tumor growth. Pharmacological inhibition of ribosome production inhibits PDAC tumor growth in animal models, pinpointing this as a potential therapeutic strategy. However, little is known about the precise mechanism of how KRAS alters ribosome production. In our preliminary study, we identified a protein named Dhx15 to be important for ribosome production only in mutant KRAS-harbouring PDAC cells, revealing the exciting possibility that ribosome production may be safely targeted without affecting normal tissues. To assess this, I will combine classic biochemical methods and new sequencing approaches to comprehensively characterize the impact of Dhx15 on the molecular mechanism of ribosome production in cells with or without KRAS mutation. As PDAC cells also frequently encounter hypoxic stress (lack of oxygen due to poor blood supply to the tumor), I will also investigate if molecular changes in ribosome production help tumor cells survive hypoxia. Using state-of-the-art biochemical, genomic, and proteomic approaches, I will map the KRAS-driven changes in ribosome production that support PDAC, revealing new vulnerabilities of PDAC tumor cells that may be therapeutically exploited.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Yan, Junran
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~